Suntronwong Nungruthai, Kanokudom Sitthichai, Duangchinda Thaneeya, Chantima Warangkana, Pakchotanon Pattarakul, Klinfueng Sirapa, Puenpa Jiratchaya, Thatsanathorn Thaksaporn, Wanlapakorn Nasamon, Poovorawan Yong
Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand.
Sci Rep. 2025 Jan 9;15(1):1454. doi: 10.1038/s41598-024-84138-0.
The ongoing emergence of SARS-CoV-2 variants, combined with antigen exposures from different waves and vaccinations, poses challenges in updating COVID-19 vaccine antigens. We collected 206 sera from individuals with vaccination-only, hybrid immunity, and single or repeated omicron post-vaccination infections (PVIs), including non-JN.1 and JN.1, and evaluated neutralization against omicron BA.5, BA.2.75, BQ.1.1, XBB.1.16, XBB.1.5, and JN.1. Neutralizing antibodies exhibited a narrow breadth against BA.5 and BA.2.75 and failed to neutralize BQ.1.1 and XBB lineages after three to five doses of the ancestral monovalent vaccine. Hybrid immunity elicited higher neutralizing titers than vaccination alone, but titers remained relatively low. A single omicron PVI elicited lower neutralization titers to all variants compared to wild-type (WT), indicating immunological imprinting. Repeated omicron PVIs, particularly JN.1, slightly mitigated these effects by increasing broad neutralization responses to all variants, though not significantly. Antigenic mapping demonstrated that XBB lineages and JN.1 are antigenically distant from WT and also evaded antibodies induced by earlier omicron variants (BA.1-5) PVIs. However, repeated JN.1 PVIs shortened this antigenic distance, indicating broader neutralization across omicron variants. These findings highlight SARS-CoV-2 immunity following various antigen boosts and the impact of repeated omicron JN.1 exposure on broad immunity, informing future COVID-19 vaccination strategies.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的不断出现,加上来自不同疫情浪潮的抗原暴露和疫苗接种,给更新新冠病毒疫苗抗原带来了挑战。我们收集了206份血清,这些血清来自仅接种疫苗、具有混合免疫以及接种疫苗后发生单次或重复奥密克戎感染(PVI)的个体,包括非JN.1和JN.1,并评估了针对奥密克戎BA.5、BA.2.75、BQ.1.1、XBB.1.16、XBB.1.5和JN.1的中和作用。在接种三至五剂原始单价疫苗后,中和抗体对BA.5和BA.2.75的广度较窄,无法中和BQ.1.1和XBB谱系。混合免疫引发的中和滴度高于单纯接种疫苗,但滴度仍然相对较低。与野生型(WT)相比,单次奥密克戎PVI对所有变体引发的中和滴度较低,表明存在免疫印记。重复的奥密克戎PVI,尤其是JN.1,通过增加对所有变体的广泛中和反应,在一定程度上减轻了这些影响,尽管效果不显著。抗原图谱显示,XBB谱系和JN.1在抗原性上与WT有很大差异,并且也能逃避早期奥密克戎变体(BA.1-5)PVI诱导的抗体。然而,重复的JN.1 PVI缩短了这种抗原距离,表明对奥密克戎变体具有更广泛的中和作用。这些发现突出了各种抗原增强后SARS-CoV-2的免疫力,以及重复暴露于奥密克戎JN.1对广泛免疫力的影响,为未来的新冠病毒疫苗接种策略提供了参考。